Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China.
Lung Cancer. 2018 Feb;116:67-72. doi: 10.1016/j.lungcan.2017.12.015. Epub 2017 Dec 29.
Primary pulmonary leiomyosarcoma (PPL) is a rare diagnosis with poorly understood clinicopathological characteristics and disease progression. What we know is derived from limited case reports, so identification of features associated with patient survival is warranted.
A population cohort study was conducted using prospectively extracted data from the Surveillance, Epidemiology and End Results (SEER) database for patients with histological diagnoses of PPL from 1973 to 2013 including demographic, treatment and outcome data.
A total of 231 patients with PPL were included (mean 65.8 ± 14.9 years-of-age). 43 were categorized with a regional stage, and 60 had localized stage, whereas 70 had distant stage. Most (60.4%) patients received cancer-directed surgery, and radiotherapy was performed for 14.1% of patients. Median overall survival (OS) was 14.0 months, and 1-, 3- and 5-year OS for PPL patients was 52.7%, 29.0% and 22.2%, respectively. Cancer-directed surgery significantly improved median OS for patients with PPL by almost 29.0 months (33.0 vs 4.0 months; p < .01). Multivariate Cox analysis showed that distant stage was independent prognostic factors for PPL (HR = 2.22, 95% CI 1.30-3.79). Conversely, cancer-directed surgery was an independent protective factor and this decreased risk of death by 57% (HR = 0.43, 95% CI 0.27-0.67) for patients with PPL.
PPL is a rare pathological lung cancer, surgical resection and distant stage were associated with prognosis. In order to understand PPL more thoroughly, more cases with adequate information are required.
原发性肺平滑肌肉瘤(PPL)是一种罕见的诊断,其临床病理特征和疾病进展尚不清楚。我们所了解的知识来源于有限的病例报告,因此有必要确定与患者生存相关的特征。
对 1973 年至 2013 年期间从监测、流行病学和最终结果(SEER)数据库中前瞻性提取的组织学诊断为 PPL 的患者的人口统计学、治疗和结局数据进行了一项人群队列研究。
共纳入 231 例 PPL 患者(平均年龄 65.8±14.9 岁)。43 例为区域性分期,60 例为局限性分期,70 例为远处分期。大多数(60.4%)患者接受了癌症定向手术,14.1%的患者接受了放疗。中位总生存期(OS)为 14.0 个月,PPL 患者的 1 年、3 年和 5 年 OS 分别为 52.7%、29.0%和 22.2%。癌症定向手术显著提高了 PPL 患者的中位 OS,几乎提高了 29.0 个月(33.0 与 4.0 个月;p<0.01)。多因素 Cox 分析显示,远处分期是 PPL 的独立预后因素(HR=2.22,95%CI 1.30-3.79)。相反,癌症定向手术是独立的保护因素,使 PPL 患者的死亡风险降低 57%(HR=0.43,95%CI 0.27-0.67)。
PPL 是一种罕见的肺部恶性肿瘤,手术切除和远处分期与预后相关。为了更深入地了解 PPL,需要更多具有充分信息的病例。